EBMT 2018 | Implications for a technique which eliminates GvHD

Denis C. Roy

Denis Claude Roy, MD, FRCP, of the University of Montreal, Montreal, Canada, is involved in developing a technique for eradicating the risk of GvHD in haploidentical stem cell transplant recipients by selectively killing the donor cells that react to host cells. In this video, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, he discusses the wide-reaching potential for this technology, as well as considerations for donor matching.

Transcript (edited for clarity):

So this right now is undergoing what we call a Phase III clinical trial, where we’re comparing it to the gold standard, or the most applied technology, but eventually, this this strategy has the potential to be applied to many many different conditions. Right now it is tested in patients with acute leukemia basically and myelodysplastic syndrome, however it could be applied to all patients with hematologic disorders. And one could even think of applying it to other conditions, even benign conditions for which patients are dying for other non-cancer diseases. So I would say all indications for which stem cell transplant is required could be amenable to this to this strategy.

There still has to be a difference between a donor and recipient, but in most instances, that is the case. With smaller families, we are now faced with the situation where we have to take people that are not perfectly matched, we don’t have the choice that when we are- our parents who had ten kids they, always had a donor available, but these days it’s hard to find somebody that’s compatible. And we’re now even thinking that this may replace unrelated stem cell transplants, so even in the setting of not having anybody in the world registry that’s compatible, we could use strategies of somebody in the family that’s only partially matched. So that is extremely exciting and opens up lots of area for for improvement.

Share this video